Sign In

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

FDA Approves Zanubrutinib For Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Oncology Practice Insider

On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa, BeiGene USA, Inc.) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read more